Pharmaceutical Technology

SEPTEMBER 23, 2022

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. In June, the company received approval from the FDA for a pneumococcal 15-valent conjugate vaccine , Vaxneuvance, for children aged between six weeks and 17 years. The suit involved two Merck patents.

FDA 69

FDA Vaccines 69

European Pharmaceutical Review

APRIL 14, 2023

Article – oligonucleotide therapeutics: The promise of telomerase inhibitors for treating blood cancer … Dr Leberer also discussed the number of drugs approved in the space: Currently, 18 are oligonucleotide drugs, with mRNA vaccines holding the same number, he noted. Eight target the liver and four target muscle.

Vaccines 86

Vaccines 86

pharmaphorum

DECEMBER 10, 2020

Shares in the big US pharma were up nearly 6% following the announcement, although the pharma stocks in general were buoyed by optimism over BioNTech/Pfizer’s COVID-19 vaccine. Tirzepatide is also taken weekly, cutting the number of injections needed to control blood sugar.

Vaccines 64

Vaccines FDA 64

European Pharmaceutical Review

MARCH 4, 2024

These biopharmaceuticals encompass a range of products including vaccines, recombinant therapeutic proteins, tissues, cells and gene therapies – all sourced from living organisms. percent through 2027. 8,9 In contrast to virus-based vectors and VLPs, another viable approach is the use of non‑viral vectors for gene and protein delivery.

FDA 88

FDA Vaccines Immunization Compounding 88

Hospital Pharmacy Europe

NOVEMBER 23, 2023

The level of annual allowed growth in sales of branded medicines will double from 2% in 2024 to 4% by 2027. The new agreement, however, sets a yearly cap on the total allowed sales value of branded medicines to the NHS each year. Sales above the cap are paid back to the Government via a levy.

Hospitals 52

Hospitals Vaccines 52

pharmaphorum

FEBRUARY 3, 2022

There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. reaching £915 billion by 2027. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9%

Compounding 52

Compounding Packaging Vaccines 52

ISPE

SEPTEMBER 29, 2023

For more than 240 years, Takeda has focused on delivering transformative treatments in the therapeutic areas of gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Patient Care 52

pharmaphorum

JANUARY 18, 2022

million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. Device innovations, connected delivery and regulatory guidance for advanced parenteral systems. The global pre-filled syringes market was valued at $1139.6

Packaging 52

Packaging FDA Documentation Vaccines 52

European Pharmaceutical Review

OCTOBER 12, 2023

With the goal of supplying cell therapies, vaccines and other essential medicines such as antibody drugs to patients, the facilities aim to address major supply challenges and navigate the intricacies of producing fragile biological products. Meath opened last month. In total, both projects represent an investment of over €1 billion.

Vaccines 84

Vaccines Dosage Pharmaceutical Companies Pharmaceutical Companies 84

pharmaphorum

JANUARY 16, 2023

Rapid growth is forecasted from 2023 onwards: some industry observers predict that the global POC and rapid Dx market projected to reach $75bn by 2027, up from $45bn in 2022, at a CAGR of 10.7%. Innovation will power the market. The fundamental engine of innovation for the global pharmaceutical industry continues.

FDA 98

FDA Pharmaceutical Companies Pharmaceutical Companies Compounding 98

ISPE

MARCH 8, 2023

Noteworthy cases were the inadvertent introduction of grade 316L stainless steel into Moder-na’s COVID-19 vaccine by the outsourced manufacturer (ROVI Pharma Industrial Services S. In the Moderna COVID-19 vaccine contamination case, three lots of the five lots affected, totaling 1.63 How Did 75M J&J Vaccines Get Ruined?

Compounding 52

Compounding Compounding Pharmacies Packaging FDA 52

pharmaphorum

JANUARY 6, 2022

IQVIA Institute models global cumulative spend on COVID-19 vaccines to be a base case of $251bn to 2026 , with spend on COVID-19 treatments, including the new oral agents and treatments of post-viral syndromes, likely to add significant incremental spend. Medicine budget constraint, structural fund largesse.

Vaccines 111

Vaccines Pharmaceutical Companies Pharmaceutical Companies 111

ISPE

SEPTEMBER 11, 2023

Sanofi Pumps $554M into New Vaccine Manufacturing Facility in Eastern France.” www.fiercepharma.com/manufacturing/sanofi-pumps-554m-into-new-vaccine-manufacturing-facility-eastern-france 41 Boccard. New Project: Evolutive Vaccines Facility for Sanofi.” www.boccard.com/evolutive-vaccines-facility-for-sanofi/ 42 Amgen.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.

Vaccines 59

Vaccines Immunization Medical Schools FDA 59

Pharmaceutical Technology

APRIL 24, 2023

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures. The approval of the mRNA Covid-19 vaccine, which is a biologic, has thrust the modality even further into the spotlight.

Vaccines 52

Vaccines Compounding Pharmaceutical Companies Pharmaceutical Companies 52

BuzzRx

AUGUST 30, 2022

Cost sharing for adult vaccines covered by Medicare Part D will be eliminated In 2020, more than 4 million Medicare beneficiaries received a vaccine covered under Part D, including 3.6 million who received the shingles vaccine.

Vaccines 52

Vaccines Insurance Packaging Immunization 52